Fact-checked by Grok 2 weeks ago

Cardiac action potential

The cardiac action potential is a transient change in the electrical potential across the plasma membrane of cardiac myocytes, initiating the coordinated of the heart muscle to pump effectively. This electrochemical event is essential for the heart's rhythmic activity, propagating from the through the conduction system to synchronize atrial and ventricular contractions. Unlike neuronal action potentials, which are brief spikes, the cardiac version features a prolonged plateau that allows sustained calcium influx, linking electrical to mechanical via excitation-contraction coupling. The action potential in ventricular myocytes is conventionally divided into five phases, each governed by specific voltage-gated ion channels and fluxes of sodium (Na⁺), potassium (K⁺), and calcium (Ca²⁺) ions. Phase 0 marks rapid , driven by the opening of fast Na⁺ channels, allowing Na⁺ influx that elevates the from approximately -90 mV to +30 mV. This phase ensures rapid conduction of the impulse across the myocardium. Phase 1 involves partial , as transient outward K⁺ currents (I_to) activate alongside Na⁺ channel inactivation, creating a notch in the potential. In phase 2, the plateau phase, the stabilizes due to a balance between inward Ca²⁺ current through L-type channels (I_Ca,L) and outward delayed rectifier K⁺ currents (I_Ks and I_Kr), lasting 200-300 ms to prolong and prevent premature re-excitation. Phase 3 is full , dominated by enhanced K⁺ efflux as Ca²⁺ channels inactivate, restoring the potential toward -90 mV. Finally, phase 4 represents the resting state, maintained by inward rectifier K⁺ currents (I_K1), with the set by the K⁺ equilibrium potential. Action potentials vary by cell type: pacemaker cells in the exhibit spontaneous phase 4 depolarization () due to funny currents (I_f) and Ca²⁺ channels, generating rhythmic impulses without external stimulation. In contrast, contractile cells require propagated signals for . Disruptions in these ionic mechanisms, such as mutations in channel genes, can lead to arrhythmias, underscoring the action potential's critical role in .

Overview

Definition and physiological role

The cardiac action potential is a transient reversal of the electrical potential across the plasma membrane of cardiac myocytes, shifting from a resting of approximately -90 to a peak of about +30 . This voltage change occurs in a rapid sequence driven by fluxes and typically lasts 200-400 milliseconds, distinguishing it from shorter action potentials in other excitable tissues. In cardiac cells, this process underlies the rhythmic electrical activity that propagates through the heart muscle, enabling synchronized contractions essential for effective blood circulation. Physiologically, the cardiac action potential serves as the critical link between electrical excitation and mechanical contraction through excitation-contraction coupling, where the depolarizing signal triggers calcium influx and subsequent myofilament activation in myocytes. This coupling ensures that the action potential not only initiates contraction but also coordinates the sequential activation of atrial and ventricular chambers, allowing for efficient to fill the ventricles followed by powerful ventricular ejection. Without this precise temporal and spatial coordination, the heart's pumping efficiency would be compromised, leading to reduced circulatory support. The basic sequence of the cardiac action potential involves to initiate , a sustained to prolong calcium entry, and to restore the resting state, collectively supporting the heart's rhythmic output of approximately 5-6 liters of blood per minute at rest. This cyclical electrical pattern, originating from cells and propagating via specialized conduction pathways, maintains continuous to meet metabolic demands. Historically, foundational insights into emerged from Sunao Tawara's 1906 description of the atrioventricular conduction system, which elucidated the anatomical basis for propagation and synchronous heartbeats, paving the way for later intracellular recordings in the mid-20th century.

Comparison to neuronal action potential

The cardiac differs markedly from the neuronal in duration and overall shape, reflecting adaptations for sustained in heart muscle versus rapid signaling in nerves. While a typical neuronal lasts approximately 2 milliseconds, the cardiac in ventricular myocytes extends from 200 to 400 milliseconds, enabling prolonged depolarization that supports effective pumping action. This extended duration in cardiac cells arises primarily from a distinct plateau phase, absent in neuronal s, which maintains the near +20 to +30 mV for much of the event before slow . Functionally, these differences underpin critical physiological roles: the prolonged refractory period in cardiac action potentials, lasting nearly the full duration of the potential, prevents premature excitations that could lead to sustained tetanic contractions incompatible with the heart's need for rhythmic filling and ejection. In contrast, the brief refractory period of neuronal action potentials (about 1-2 milliseconds) allows high-frequency firing, up to hundreds of times per second, essential for rapid information transmission. This adaptation ensures the heart avoids arrhythmias from overlapping contractions while neurons prioritize speed and repetitiveness. Ionically, the cardiac action potential relies more heavily on calcium influx during the plateau phase to balance efflux and sustain , whereas neuronal action potentials depend predominantly on rapid sodium influx for and efflux for quick , lacking a calcium-dominated maintenance phase. These ionic distinctions contribute to the slower in cardiac cells, optimizing for over neural speed.

Phases of the action potential

Phase 4: Diastolic depolarization and automaticity

In non-pacemaker cardiac cells, such as ventricular and atrial myocytes, phase 4 represents a stable resting of approximately -90 mV, primarily maintained by the inward rectifier potassium current (IK1), which conducts outward K+ ions to stabilize the potential near the K+ equilibrium potential and prevents spontaneous . This stability ensures that these cells remain quiescent until excited by propagating action potentials from pacemaker regions. In contrast, pacemaker cells exhibit during phase 4 through diastolic , where the membrane potential gradually rises without external stimulation. In (SAN) cells, the primary pacemaker site, phase 4 involves a slow that the membrane from about -60 mV to a of -40 mV over 100-300 ms, leading to spontaneous action potentials at rates of 60-100 beats per minute. Secondary pacemakers, such as those in the atrioventricular (AV) node (40-60 beats per minute) and (20-40 beats per minute), display similar but slower depolarization slopes, which determine their intrinsic firing rates and serve as backups if the SAN fails. The slope of this diastolic depolarization directly influences the rate, with steeper slopes accelerating the time to . Automaticity in these cells arises from multiple integrated mechanisms, including the funny current (If), mediated by hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, which provides an inward Na+/K+ current that initiates early depolarization following hyperpolarization at the end of phase 3. Later phases of depolarization are driven by the decay of outward K+ currents (such as IK) and the Ca2+ clock mechanism, involving spontaneous sarcoplasmic reticulum Ca2+ release that activates the Na+/Ca2+ exchanger current (INCX), generating an inward current to further depolarize the membrane. These processes couple with the voltage clock (membrane ion channels) to ensure rhythmic firing. The initial depolarization rate due to If can be approximated by the equation: \frac{dV}{dt} \approx g_{If} (V - E_{If}) where g_{If} is the conductance of If and E_{If} is its reversal potential (around -20 to -10 ). Autonomic modulation, via sympathetic or parasympathetic inputs, can alter the slope of diastolic depolarization to adjust .

Phase 0: depolarization

Phase 0 of the cardiac action potential represents the depolarization phase, initiated when the membrane potential reaches , triggered either by gradual diastolic depolarization in phase 4 of pacemaker cells or by propagated electrical signals from adjacent cells in working myocardium. In non-pacemaker cells (e.g., atrial and ventricular myocytes), the threshold is approximately -70 to -65 , activating voltage-gated sodium channels and leading to a swift influx of sodium ions that drives the upstroke, with the voltage rapidly shifting from the resting of about -90 to a peak of +20 to +30 within 1 to 2 milliseconds, overshooting the sodium equilibrium potential (E_Na, typically around +60 ) due to the high electrochemical driving force for Na^+ entry at the onset. This fast upstroke is powered by the transient fast sodium current (I_Na), which reaches peak densities of 200 to 300 pA/pF in ventricular myocytes, reflecting the high density of sodium channels and their gating kinetics. The activation of these channels occurs with time constants on the order of 0.1 to 0.5 ms, followed quickly by inactivation to prevent prolonged . In pacemaker cells (e.g., ), the take-off threshold is higher, around -50 to -40 mV, and the upstroke is slower (upstroke 10-40 V/s vs. 100-500 V/s in non-pacemaker cells), primarily driven by Ca²⁺ influx through L-type voltage-gated calcium channels rather than Na⁺ channels (which are largely inactivated at diastolic potentials near -60 mV), reaching a peak of approximately 0 to +20 mV. The magnitude and speed of phase 0 in non-pacemaker cells are critical for conduction , which averages 0.5 to 1 m/s in the working atrial and ventricular myocardium but increases to 2 to 4 m/s in the specialized due to their larger diameter, higher density, and efficient coupling. Mathematically, the sodium current is modeled as I_{Na} = g_{Na} \, m^3 \, h \, (V - E_{Na}) where g_{Na} is the maximum sodium conductance, m is the activation gate variable (rising rapidly with depolarization), h is the inactivation gate variable (declining shortly after activation), V is the membrane potential, and E_{Na} is the sodium reversal potential; this formulation, adapted from the Hodgkin-Huxley framework, captures the voltage- and time-dependent behavior in cardiac models.

Phase 1: Initial repolarization

Phase 1 of the cardiac action potential, known as initial , begins immediately after the peak of phase 0 rapid depolarization, typically within milliseconds of the upstroke reaching its maximum. This phase lasts for a brief duration of approximately 2-5 in ventricular myocytes, during which the membrane potential partially reverses from its overshoot of around +30 mV to a notch level near 0 mV or slightly negative values such as -15 mV. The transient nature of this repolarization creates a characteristic "notch" in the action potential , particularly evident in certain cardiac regions. The mechanisms driving phase 1 involve a balance of outward and diminishing inward currents. The primary contributor is the activation of the transient outward potassium current (I_{To}), a voltage-gated K^+ efflux that rapidly activates upon depolarization and peaks early. Concurrently, the fast inactivation of voltage-gated Na^+ channels terminates the inward Na^+ current from phase 0, reducing depolarizing influx; incomplete Na^+ inactivation and chloride currents (I_{Cl}) provide minor additional outward components in some cell types. The I_{To} current is mathematically represented as I_{To} = g_{to} \cdot (V - E_K) \cdot a \cdot (1 - i), where g_{to} is the maximal conductance, V is the membrane potential, E_K is the potassium equilibrium potential, a is the activation gating variable, and i is the inactivation gating variable; this formulation captures the current's rapid rise and subsequent decay during early repolarization. Regional variations in phase 1 are prominent across the ventricular wall, with a sharper and deeper notch in epicardial and subepicardial myocytes compared to endocardial cells, where the repolarization is shallower and slower (e.g., ~2.4 ms vs. ~4.7 ms for the early repolarization phase). This difference arises from higher I_{To} density in epicardial regions, leading to more pronounced K^+ efflux. Functionally, phase 1 establishes the voltage level for entry into the plateau phase, preventing excessive prolongation of the action potential while modulating the through its influence on overall timing and . Reduced I_{To} activity, as seen in certain , can diminish this notch and alter arrhythmogenic vulnerability.

Phase 2: Plateau phase

The plateau phase, or phase 2, of the cardiac action potential is characterized by a sustained that maintains the relatively stable, typically between 0 and +20 , for a duration of approximately 100-200 in ventricular myocytes. This phase is unique to cardiac cells and distinguishes them from neuronal action potentials by prolonging the refractory period and allowing coordinated . The maintenance of the plateau relies on a delicate ionic balance where inward calcium current through L-type voltage-gated calcium channels (ICa,L) counteracts outward potassium currents via the slow (IKs) and rapid (IKr) components of the delayed rectifier channels. This equilibrium results in a near-zero net membrane current, as described by the approximate relation: I_\text{net} \approx I_\text{Ca,L} + I_\text{Ks} + I_\text{Kr} \approx 0 where the inward ICa,L is balanced by the outward IKs and IKr to sustain the voltage plateau. The IKs and IKr currents, first distinguished in ventricular myocytes, activate with distinct time courses during this phase to prevent premature . During phase 2, the influx of Ca2+ through L-type channels plays a critical role in excitation- coupling by triggering (CICR) from the via ryanodine receptors (RyR2). This process amplifies the cytosolic Ca2+ signal, enabling actin-myosin cross-bridge formation and myocardial . The of phase 2 exhibits regional variations, lasting longer in ventricular myocytes (about 150 ms) compared to atrial myocytes (around 80 ms), reflecting differences in expression and contributing to heterogeneous across the heart. Additionally, phase 2 shortens with increasing due to enhanced IKs activation via β-adrenergic stimulation, which helps adapt to faster pacing and prevent excessive prolongation.

Phase 3: Final repolarization

Phase 3 of the cardiac action potential represents the final phase, during which the rapidly returns from approximately 0 mV to the of about -90 mV, typically lasting 50-100 ms in ventricular myocytes. This phase is initiated as the inward calcium current (I_Ca) inactivates, shifting the balance toward net outward currents that dominate . The primary ionic currents driving phase 3 are the rapid delayed rectifier potassium current (I_Kr), the slow delayed rectifier potassium current (I_Ks), and the inward rectifier potassium current (I_K1). I_Kr and I_Ks, mediated by (KCNH2) and KCNQ1/KCNE1 channels respectively, activate during the plateau phase and contribute increasingly to outward K^+ efflux as progresses, with I_Kr playing a more prominent role early in phase 3 due to its faster activation kinetics. I_K1, carried by Kir2.x channels, becomes significant at more negative potentials (below -20 mV), stabilizing the final approach to through its strong inward , which limits outward current at depolarized levels but enhances it near . The total repolarizing current can be expressed as: I_{\text{total K}} = I_{\text{Kr}} + I_{\text{Ks}} + I_{\text{K1}} where, for example, I_{\text{Kr}} = g_{\text{Kr}} \cdot (V - E_{\text{K}}) \cdot f_{\text{rect}}(V), with g_{\text{Kr}} as the conductance, V the membrane potential, E_{\text{K}} the potassium equilibrium potential, and f_{\text{rect}}(V) a voltage-dependent rectification factor accounting for rapid inactivation at depolarized potentials. Repolarization during phase 3 exhibits spatial and temporal heterogeneity across the myocardium, reflected clinically by the on the electrocardiogram (ECG), which approximates the duration of ventricular repolarization (phases 2 and 3 combined). Increased dispersion of repolarization—variations in action potential duration between regions like epicardium, , and mid-myocardium—can predispose to arrhythmias such as by creating substrates for re-entry. The duration of phase 3 demonstrates rate dependence, shortening at faster heart rates due to incomplete recovery of I_Kr and I_Ks from inactivation, which reduces their availability and accelerates to maintain diastolic intervals. This adaptive mechanism helps prevent excessive prolongation of the action potential at high rates but can be disrupted in conditions reducing repolarization reserve, such as selective I_Kr .

Ionic basis

Voltage-gated sodium channels

Voltage-gated sodium channels, primarily the Nav1.5 isoform encoded by the gene, are integral membrane proteins responsible for the rapid influx of sodium ions that drives the upstroke of the cardiac action potential. The channel complex consists of a pore-forming α-subunit (Nav1.5), which spans approximately 2,000 and features four homologous domains (DI–DIV) each with six transmembrane segments (S1–S6), connected by intracellular loops. Unlike neuronal sodium channels, cardiac Nav1.5 is tetrodotoxin-resistant, exhibiting low sensitivity to this toxin due to specific substitutions in the region, which allows it to function effectively in the cardiac environment. Auxiliary β-subunits (β1–β4), encoded by separate genes, associate with the α-subunit to modulate channel trafficking, gating, and subcellular localization, forming a macromolecular complex essential for proper cardiac excitability. The kinetics of Nav1.5 activation and inactivation are finely tuned for rapid signaling. Upon membrane depolarization to (around -70 mV), voltage-sensing domains in the S4 segments trigger fast activation within milliseconds, with time constants typically 0.3–1 ms, opening the inner pore to permit sodium influx. Fast inactivation follows swiftly via the IFM motif in the DIII–DIV linker, occluding the pore with time constants of 1–3 ms, while slower inactivation processes contribute to late currents under pathological conditions. Recovery from inactivation occurs biexponentially at resting potentials, with a fast component of 5–10 ms enabling rapid reavailability for subsequent potentials, crucial for high-frequency conduction in the heart. In ventricular cardiomyocytes, the peak sodium current (INa) density mediated by Nav1.5 ranges from 20–50 pA/pF, supporting efficient and propagation. This is regionally heterogeneous, with higher Nav1.5 expression and excitability in compared to working myocardium, facilitated by elevated levels of β1 and β3 subunits that enhance channel density and conduction velocity. Nav1.5 serves as the primary driver of phase 0 rapid in cardiomyocytes. Mutations in disrupt Nav1.5 function, leading to inherited arrhythmias; loss-of-function variants cause by reducing INa availability, while gain-of-function mutations, such as those prolonging recovery or enhancing late currents, underlie long QT syndrome type 3 (LQT3). Pharmacologically, Nav1.5 is targeted by class I antiarrhythmic drugs, which bind to the inner pore in the inactivated state to block sodium influx; for example, lidocaine (class Ib) exhibits fast onset and offset, preferentially affecting ischemic or rapidly firing tissue.

Voltage-gated calcium channels

Voltage-gated calcium channels (VGCCs) play a pivotal role in the cardiac action potential by mediating calcium influx that sustains the plateau phase and couples electrical excitation to mechanical . These channels open in response to membrane depolarization, allowing Ca²⁺ entry which triggers (CICR) from the , thereby amplifying intracellular Ca²⁺ signals essential for cardiomyocyte . In cardiac myocytes, the primary VGCC subtypes are L-type and channels. L-type channels, encoded by Cav1.2 (α1C) and Cav1.3 (α1D) subunits, are high-voltage-activated, long-lasting, and sensitive to dihydropyridines such as . channels, comprising Cav3.1 (α1G) and Cav3.2 (α1H) subunits, are low-voltage-activated and exhibit transient currents, activating at more negative potentials than L-type channels. L-type channels activate around -30 mV, with peak currents near 0 mV, and inactivate slowly over approximately 100 ms due to both voltage- and calcium-dependent mechanisms, contributing a (I_{Ca,L}) of 5-10 / in ventricular myocytes. This prolonged influx balances repolarizing currents during phase 2 of the action potential. T-type channels, in contrast, activate at potentials below -50 mV and inactivate more rapidly, generating transient Ca²⁺ currents that support subtle without significant contribution to the plateau. Functionally, L-type channels are central to CICR, where their Ca²⁺ influx initiates opening in the , driving . In (SAN) pacemaker cells, channels facilitate phase 4 diastolic , enhancing by providing an early Ca²⁺ current during the . Pharmacologically, L-type channels are targeted by non-dihydropyridine blockers like verapamil, which bind to the channel's inner pore to inhibit Ca²⁺ entry, reducing and contractility for therapeutic rate control in arrhythmias such as . Dihydropyridines preferentially block L-type over channels, offering selectivity for vascular and cardiac effects. Recent studies highlight an underestimated role for VGCCs in action potentials of stem cell-derived cardiomyocytes, where modulating L- and channel expression via genetic or pharmacological means enhances electrophysiological maturity and Ca²⁺ handling, improving their utility in regenerative models. Beta-adrenergic stimulation further upregulates I_{Ca,L} via , prolonging the plateau under sympathetic influence.

Potassium channels

Potassium channels play a crucial role in maintaining the and facilitating during the cardiac action potential by allowing K⁺ efflux. These channels are diverse, encompassing inward rectifiers, delayed rectifiers, and transient outward types, each contributing to specific phases of the action potential waveform. The inward rectifier potassium current, I_{K1}, primarily encoded by the Kir2.1 subunit (KCNJ2 gene), stabilizes the near the K⁺ equilibrium potential during phase 4 and contributes to final in phase 3. I_{K1} exhibits strong inward , conducting larger inward currents at hyperpolarized potentials and smaller outward currents near the due to voltage-dependent block by intracellular polyamines and Mg²⁺. In ventricular myocytes, I_{K1} density is relatively high, typically 10-20 pA/pF at potentials around -80 mV, enabling stable excitability, whereas it is markedly lower in (SAN) cells, which supports by reducing hyperpolarizing influence.00331-3/fulltext) Delayed rectifier potassium currents include the rapid component I_{Kr}, formed by channels (KCNH2 gene) with beta-subunit association, and the slow component I_{Ks}, mediated by KCNQ1 alpha-subunits co-assembled with KCNE1 (). I_{Kr} activates rapidly upon but features fast C-type inactivation, leading to inward and peak outward current during , particularly in phase 3. In contrast, I_{Ks} shows slow activation kinetics and accumulates over successive s, increasing with to shorten action potential duration and prevent excessive prolongation at faster rates. These currents provide the primary repolarizing force in ventricular and atrial myocytes, with I_{Kr} dominating under normal conditions and I_{Ks} becoming more prominent during sympathetic stimulation.73849-4/fulltext) The transient outward potassium current, I_{to}, is primarily carried by Kv4.3 alpha-subunits (KCND3 gene) in association with auxiliary subunits like KChIP2, contributing to early in phase 1. I_{to} activates quickly upon and inactivates rapidly, producing a transient outward surge that notches the action potential peak, with regional variations such as prominence in epicardium versus . Mutations in genes encoding these channels underlie inherited arrhythmias. Loss-of-function mutations in (KCNH2) cause type 2 (LQT2) by reducing I_{Kr}, prolonging and increasing risk. Similarly, KCNQ1 mutations lead to LQT1 with I_{Ks} impairment, often triggered by exercise, while homozygous or compound heterozygous variants in KCNQ1 result in , combining severe QT prolongation with congenital deafness.00008-8/fulltext) Pharmacologically, class III antiarrhythmics like sotalol block I_{Kr}, prolonging the QT interval to suppress reentry but risking proarrhythmia through excessive repolarization delay. This blockade is more pronounced at slower heart rates due to I_{Kr}'s kinetics, highlighting the concept of repolarization reserve where multiple potassium currents collectively ensure robust repolarization.

Hyperpolarization-activated channels

Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels constitute a family of four isoforms, HCN1–HCN4, that assemble as homotetramers or heterotetramers to form the molecular basis of the funny current (I_f) in cardiac cells. Each isoform shares a common with six transmembrane segments, a positively charged S4 voltage-sensing domain, and a cyclic nucleotide-binding domain (CNBD) in the that binds or cGMP, with binding shifting the voltage dependence of activation toward less negative potentials and enhancing I_f amplitude. This structural feature allows HCN channels to integrate electrical and biochemical signals, particularly in pacemaker regions.31739-1) These channels activate upon membrane hyperpolarization, typically in the range of -50 to -100 mV, with half-maximal activation around -60 to -70 mV depending on the isoform; activation kinetics are relatively slow, with time constants of 100–500 ms at physiological temperatures. I_f is a nonselective cation current permeable to both Na^+ and K^+ ions in a 1:3 ratio, yielding a reversal potential (E_{I_f}) of approximately -10 to -20 mV, which renders it inward and depolarizing under diastolic conditions. In the sinoatrial node (SAN), HCN4 is the dominant isoform, comprising over 70% of total HCN expression, while HCN1 and HCN2 are expressed at lower levels; this distribution supports I_f as a key driver of phase 4 diastolic depolarization, contributing substantially—up to 75% of the current density—to the slope of spontaneous depolarization in SAN myocytes. Recent research as of April 2025 has revealed sex-specific differences, with higher HCN1 expression in female SAN contributing to intrinsically faster heart rates. The I_f current sets the pace of diastolic depolarization in phase 4, establishing the threshold for the next and thus regulating basal ; sympathetic stimulation via β-adrenergic receptors elevates levels, enhancing I_f to accelerate pacemaking. HCN channels have emerged as targets for biological s, with 2024 advances demonstrating that engineered overexpression of HCN2 or HCN4 in cell-derived cardiomyocytes can generate stable, autonomous pacemaker activity in preclinical models, offering potential alternatives to electronic devices. Pharmacologically, acts as a selective open-state blocker of HCN channels, inhibiting I_f with use-dependence to lower by 10–20 bpm in patients, improving outcomes without impacting .

Propagation and conduction

Gap junctions and cell coupling

Gap junctions are specialized intercellular channels that facilitate direct electrical and metabolic coupling between adjacent cardiomyocytes, enabling the synchronized of action potentials across the myocardium. These structures are essential for coordinated cardiac contraction, as they allow the passive flow of ions and small molecules, such as and sodium, between cells without traversing the . In the heart, gap junctions are primarily composed of proteins, which assemble into hemichannels called ; each consists of six subunits forming a hexameric , and docking of two opposing from adjacent cells creates the complete channel. The predominant connexin isoform in ventricular myocardium is (Cx43), which forms the majority of junctions in working ventricular myocytes, while connexin 40 (Cx40) is more abundant in atrial myocytes and the specialized conduction system, such as the and . Cx43 and Cx40 exhibit distinct biophysical properties, with Cx40 supporting higher conductance suitable for rapid impulse transmission in conductive tissues. These proteins are integral membrane proteins with four transmembrane domains, two extracellular loops, one intracellular loop, and a carboxyl-terminal tail that influences and regulation. Functionally, gap junctions provide low-resistance electrical pathways that underpin the velocity and fidelity of propagation, with individual Cx43 channels exhibiting single-channel conductances typically ranging from 50 to 100 under physiological conditions. This conductance allows efficient current spread, minimizing voltage gradients between cells and ensuring uniform . In the conduction system fibers, junctions similarly couple cells to support rapid longitudinal propagation. Gap junctions are predominantly distributed at the intercalated discs, the specialized end-to-end junctions between cardiomyocytes, where they cluster in high-density plaques to optimize . This arrangement contributes to anisotropic conduction properties in the myocardium, with faster impulse propagation along the longitudinal axis of fibers (due to aligned junctions) compared to the transverse , promoting efficient directional spread of excitation. In pathophysiological states, such as myocardial ischemia, Cx43 expression and are reduced, leading to uncoupling, slowed conduction, and increased susceptibility to reentrant arrhythmias. Ischemic conditions promote and lateralization of Cx43 away from intercalated discs, impairing intercellular current flow and creating heterogeneous conduction that facilitates arrhythmogenesis. Regulation of function occurs primarily through post-translational modifications, particularly of Cx43 at multiple serine residues in its carboxyl terminus by kinases such as and A, which modulates channel permeability, open probability, and overall conductance. For instance, at serine 368 decreases unitary conductance and alters , thereby influencing the of spread and maintaining synchronized beating under varying physiological demands. , conversely, can reduce coupling efficiency, highlighting the dynamic role of these modifications in .

Refractory periods

The absolute refractory period in cardiac myocytes encompasses phases 0 through 2 of the , lasting approximately 200–250 ms, during which the cell is completely inexcitable and incapable of generating a new regardless of stimulus strength. This inexcitability arises primarily from the inactivation of voltage-gated sodium channels following the rapid in phase 0, preventing their reactivation until partial occurs. The period ensures coordinated contraction and protects against premature excitations that could disrupt normal rhythm. It ends midway through phase 3 of . The relative refractory period follows, occurring in the late phase 3 and extending into early phase 4, with a duration of about 50 ms. During this interval, the has repolarized sufficiently for some s to recover, but the excitability threshold remains elevated due to incomplete recovery of conductances and partial availability, necessitating a suprathreshold stimulus to initiate a new . This phase renders the tissue vulnerable to strong premature stimuli, potentially leading to asynchronous depolarizations. Functionally, the combined refractory periods prolong the diastolic interval, allowing adequate ventricular filling and limiting the maximum to 200–250 beats per minute by enforcing a minimum cycle length. They are quantified experimentally through strength-interval curves, which relate stimulus intensity to the timing of test pulses following a conditioning beat to determine the ; these curves reveal prolonged refractory durations in pathological states like cardiac , where altered dynamics extend inexcitability. Clinically, alterations in refractory period duration contribute to arrhythmogenesis; for instance, catecholamine excess shortens the period, reducing the excitable gap and promoting reentrant . Conversely, potassium channel blockers lengthen the refractory period by delaying , thereby suppressing reentry-based arrhythmias and serving as a therapeutic strategy in conditions like .

Conduction system overview

The cardiac conduction system comprises specialized tissues that generate and propagate action potentials to ensure coordinated atrial and ventricular contractions. The (SAN), situated at the junction of the and right atrium, functions as the primary , spontaneously initiating action potentials at a rate of 60-100 beats per minute through phase 4 diastolic . From the SAN, the electrical impulse spreads rapidly across the atria via internodal pathways—three preferential tracts (anterior, middle, and posterior)—which facilitate preferential conduction from the right to the left atrium. This atrial activation typically completes within approximately 80 ms, enabling synchronous atrial . The impulse then converges on the atrioventricular (AV) node, located near the in the , where conduction slows significantly to about 0.05 m/s, introducing a delay of roughly 100 ms. This pause allows complete atrial emptying before ventricular activation begins and can be further modulated by vagal autonomic influences that enhance the delay. Beyond the AV node, the penetrates the , bifurcating into left and right bundle branches that distribute the signal via the Purkinje fiber network. These fibers enable rapid ventricular conduction at velocities of 2-4 m/s, attributed to their higher density of voltage-gated sodium channels, resulting in activation progressing from apex to base in 40-60 ms for efficient ventricular contraction. This sequence is reflected in the electrocardiogram as the (atrial depolarization), (ventricular depolarization), and (ventricular repolarization). The conduction system's development originates from cardiac progenitor cells in the embryonic , which differentiate into nodal and conducting tissues during weeks 4-7 of through signaling pathways involving T-box transcription factors and . Disruptions in this process, such as genetic mutations or environmental factors, can lead to congenital conduction blocks, including or sinoatrial node dysfunction. Integration across the system depends on electrical coupling via gap junctions, ensuring seamless propagation, while inherent automaticity gradients—decreasing from the (fastest) through the AV node and —prevent dominance by ectopic foci by allowing the primary to override subsidiary ones under normal conditions.

Physiological regulation

Autonomic nervous system influences

The exerts profound control over the cardiac action potential through sympathetic and parasympathetic branches, enabling rapid adjustments in and conduction to meet physiological demands. Sympathetic activation, primarily via β-adrenergic receptors, enhances excitability and accelerates , while parasympathetic input promotes hyperpolarization and slows pacemaking, maintaining a dynamic balance that fine-tunes . Sympathetic stimulation, mediated by norepinephrine release from terminals, activates β-adrenergic receptors coupled to Gs proteins, increasing intracellular cAMP levels and activating (PKA). This pathway augments the hyperpolarization-activated funny current (If) through HCN channels by shifting their activation curve to more positive voltages and increasing conductance, thereby accelerating the phase 4 diastolic depolarization in (SAN) cells. PKA also phosphorylates L-type calcium channels (ICa,L), enhancing their open probability and peak current to boost phase 0 upstroke velocity and calcium influx. Additionally, PKA phosphorylates the KCNQ1/KCNE1 channel complex, increasing the slowly activating delayed rectifier potassium current (IKs) to accelerate phase 3 and shorten action potential duration (APD), which supports higher heart rates by allowing more complete ventricular filling. These changes collectively accelerate phase 4 depolarization and reduce APD, facilitating and inotropic enhancements during stress. In contrast, parasympathetic (vagal) stimulation releases , which binds to muscarinic M2 receptors coupled to Gi/o proteins, inhibiting and reducing /PKA activity while directly activating G-protein-gated inward rectifier (GIRK) channels via Gβγ subunits. This opens IK,ACh channels, causing an outward current that hyperpolarizes the membrane, slows SAN phase 4 , and reduces firing rate. In the atrioventricular node (AVN), IK,ACh activation prolongs conduction delay by hyperpolarizing nodal cells and suppressing excitability, contributing to the overall bradycardic effect. The interplay between these branches maintains basal heart rate around 60 under parasympathetic dominance at rest, while sympathetic "fight-or-flight" activation can elevate it to approximately 200 through enhanced If, ICa,L, and IKs alongside reduced . These responses are coordinated via arcs, such as the baroreceptor , where arterial pressure changes detected by carotid and aortic modulate autonomic outflow to stabilize and . In , autonomic imbalance—characterized by sympathetic overdrive and parasympathetic withdrawal—predisposes to tachyarrhythmias by prolonging APD heterogeneity and increasing ectopic triggers, exacerbating arrhythmogenic risk.

Hormonal and pharmacological modulation

Hormonal modulation of the cardiac occurs primarily through endocrine influences that alter expression and function, thereby affecting duration (), conduction velocity, and overall excitability. hormone, particularly (T3), increases the L-type calcium (I_{Ca,L}) while simultaneously enhancing outward such as the transient outward (I_{to}) and delayed rectifier (I_{Ks} and I_{Kr}), resulting in a net shortening of . This effect is observed in ventricular myocytes, where acute T3 exposure (0.1 μM for 5 minutes) shortens by approximately 24%, promoting faster and potentially increasing the risk of arrhythmias in hyperthyroid states. Aldosterone enhances the inward rectifier (I_{K1}) independently of activation in certain contexts, such as during ischemia-reperfusion, which helps stabilize the resting but increases arrhythmogenic dispersion of and risk of premature ventricular contractions during ischemia-reperfusion injury. Chronic exposure to aldosterone can lead to structural remodeling that prolongs in some models. Pharmacological agents target specific ion channels to modulate characteristics, offering therapeutic control over and rhythm. Class III antiarrhythmics, such as , prolong phase 3 by blocking the rapid component of the delayed rectifier (I_{Kr}), extending APD and the to suppress re-entrant arrhythmias. This effect is prominent in ventricular tissue, where increases duration without significantly altering phase 0 upstroke velocity. Beta-blockers, including agents like metoprolol and , reduce I_{Ca,L} by inhibiting β-adrenergic receptor signaling, which decreases levels and PKA-mediated of L-type calcium channels, thereby shortening the plateau phase and slowing conduction in working myocardium. In pacemaker cells, beta-blockers also diminish the hyperpolarization-activated funny (I_f) mediated by HCN channels, reducing spontaneous rates and lowering . provides selective inhibition of HCN channels (primarily HCN4), blocking I_f in cells to decrease pacemaker firing without affecting contractility, achieving rate reduction in patients. Emerging therapies, including , aim to create biological pacemakers by overexpressing HCN channels via viral vectors, such as AAV-mediated delivery of HCN4, to generate ectopic and reduce reliance on electronic devices. These approaches, advanced in preclinical models as of 2024, modulate phase 4 to establish stable rhythms in bradycardic conditions. Dose-response considerations are critical for agents like , a III that prolongs via I_{Kr} block; therapeutic doses (160-320 mg/day) extend beneficially, but exceeding 320 mg increases risk to 5% due to excessive delay. Narrow therapeutic windows necessitate ECG monitoring to balance antiarrhythmic efficacy against proarrhythmic potential. Recent advancements in 2025 utilize human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in models to evaluate effects on morphology, enabling of prolongation and early afterdepolarizations for safer pharmacological development.

Clinical and research implications

Arrhythmias linked to action potential changes

Changes in the cardiac (AP) can disrupt normal electrical stability, predisposing the heart to arrhythmias through mechanisms such as triggered activity, reentry, or abnormal impulse generation. These alterations often involve dysfunction, leading to prolonged or shortened AP duration (), exaggerated notches, or unstable , which create substrates for malignant rhythms like or (VF). In (LQTS), loss-of-function mutations in potassium channels reduce the rapid (IKr) and slow (IKs) delayed rectifier currents, prolonging phases 2 and 3 of the AP and extending APD. This prolongation reactivates L-type calcium channels (ICaL), promoting early afterdepolarizations (EADs) that manifest as triggered activity. EADs can initiate , a polymorphic that degenerates into VF, by creating heterogeneous and facilitating reentrant circuits. Short QT syndrome (SQTS) features gain-of-function mutations in channels, such as KCNH2 or KCNQ1, which enhance outward K+ currents and accelerate phase 3 , resulting in shortened APD and . The abbreviated increases the risk of reentry, particularly through the R-on-T phenomenon, where a encroaches on the vulnerable phase, precipitating atrial or . Brugada syndrome arises from loss-of-function in sodium channels (), which diminishes the inward INa current during phase 0, exaggerating the phase 1 notch caused by the transient outward current () in right ventricular epicardium. This notch can lead to loss of the AP dome, generating heterogeneous loss of excitability and phase 2 reentry, which underlies ST-segment elevation on ECG and episodes of VF. Cardiac alternans refers to beat-to-beat variability in , often driven by instabilities in calcium handling, such as sarcoplasmic reticulum Ca2+ release refractoriness and uptake dynamics, which bidirectionally couple with membrane voltage to amplify dispersion. This instability serves as a precursor to fibrillation by promoting spatially discordant alternans and wavebreaks, as evidenced in recent studies linking it to increased arrhythmogenic risk through enhanced dispersion of . Ectopic activity, or ectopy, can stem from abnormal phase 4 depolarization due to enhanced hyperpolarization-activated "funny" current (If) mediated by HCN channels, which steepens the diastolic depolarization slope in non-pacemaker cells like or ventricular myocytes. This abnormal generates premature beats or triggered activity, contributing to tachyarrhythmias, particularly under sympathetic stimulation that upregulates If.

Therapeutic targets and emerging advances

Therapeutic targets in cardiac action potential management primarily focus on modulating ion channels and conduction to treat arrhythmias, with antiarrhythmic drugs classified under the Vaughan-Williams system representing key interventions. Class Ia agents, such as quinidine, block both sodium (Na⁺) and potassium (K⁺) channels, prolonging the and while suppressing premature beats in supraventricular and ventricular tachycardias. Class Ic drugs, like , primarily inhibit Na⁺ channels to slow conduction velocity and terminate reentrant arrhythmias such as by stabilizing phase 0 . These agents target the rapid upstroke and repolarization phases of the action potential to restore normal rhythm, though their use requires monitoring for proarrhythmic risks like due to excessive APD prolongation. Implantable devices provide non-pharmacological control by directly influencing initiation and termination. Pacemakers deliver electrical stimuli to override abnormal in sinoatrial or dysfunction, ensuring paced s supplant ectopic foci and maintain appropriate heart rates. Implantable cardioverter-defibrillators (ICDs) monitor surface electrocardiograms reflecting underlying changes, detecting or fibrillation through rate and morphology criteria derived from patterns, then delivering shocks or antitachycardia pacing to restore . These devices have significantly reduced sudden cardiac death in high-risk patients by intervening at critical propagation failures. Emerging gene therapies aim to engineer biological pacemakers by overexpressing hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, which generate the funny current (I_f) responsible for diastolic in phase 4 of the action potential. Adeno-associated virus-mediated HCN4 overexpression in animal models creates autonomous pacemaking sites that respond to autonomic modulation, with preclinical studies demonstrating stable rates around 60-80 beats per minute in canine and porcine models. A 2024 review in Circulation Research highlights these advances along with ongoing challenges in long-term expression and integration. Dual-gene approaches combining HCN with other ion channels further enhance reliability, as noted in recent translational studies. Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) serve as advanced models for dissecting subtypes and accelerating drug screening. These cells exhibit heterogeneous s mimicking atrial-like (shorter APD, prominent I_Kur) and ventricular-like (longer APD, I_Ks dominance) profiles, enabling subtype-specific assessments for new antiarrhythmics. In 2025 studies, hESC-CM platforms have identified subtype-selective effects of modulators, such as enhanced atrial in I_Kur-targeted compounds, facilitating personalized screening pipelines that predict clinical proarrhythmia risks more accurately than animal models. As of January 2025, clinical trials of human pluripotent stem cell-derived cardiomyocytes for cardiac repair and show promising safety profiles, with ongoing evaluations of efficacy in regenerative applications. This approach has streamlined high-throughput testing, reducing development timelines for therapies targeting variability in diseased states. Looking ahead, offers precise, non-invasive control of cardiac action potentials through light-sensitive opsins like channelrhodopsin-2, which depolarize targeted cardiomyocytes upon illumination to suppress or initiate rhythms. Preclinical applications in short and long syndromes demonstrate that optogenetic shortening or prolongation of prevents alternans and reentry, with 2025 advancements enabling sustained pacing in hearts at rates up to 300 beats per minute without tissue damage. Similarly, strategies to enhance reserve—via pharmacological upregulation of K⁺ currents like I_Ks—aim to stabilize and avert beat-to-beat alternans, a precursor to , as evidenced by reduced inducibility in models treated with late sodium current inhibitors. These innovations promise transformative shifts toward gene- and light-based therapies, minimizing reliance on invasive interventions.

References

  1. [1]
    Physiology, Action Potential - StatPearls - NCBI Bookshelf - NIH
    An action potential is a rapid sequence of changes in the voltage across a membrane. The membrane voltage, or potential, is determined at any time by the ...
  2. [2]
    Cardiac Ion Channels | Circulation: Arrhythmia and Electrophysiology
    Apr 1, 2009 · This review describes the generation of the normal cardiac action potential. The properties of the major ionic currents are the examined in detail.
  3. [3]
    Cardiac transmembrane ion channels and action potentials
    In the first part of this review, current knowledge on the differences in ion channel expression and properties of the ionic processes that determine the ...
  4. [4]
    Cardiac Physiology & Electrophysiology - TMedWeb
    Oct 3, 2025 · By convention the cardiac action potential is subdivided into 5 distinct phases (0 through 4) (see Figure 5). The phases are designated: phase ...
  5. [5]
    Action Potentials in Cardiac Contractile Muscle Cells - EdTech Books
    Recall that the major phases of the action potential for skeletal muscle cells and axons, are depolarization, repolarization, and hyperpolarization. The opening ...
  6. [6]
    Cardiac Action Potentials - Conduction System Tutorial
    Action potentials from such cells are also characterized by a slower initial depolarization phase, a lower amplitude overshoot, a shorter and less stable ...
  7. [7]
    A comparative review on heart ion channels, action potentials ... - NIH
    Sep 8, 2021 · This review compares types of human action potentials, the dominant ion currents during action potential phases, alteration in ion channels activities in ...
  8. [8]
    Cardiac ion channels in health and disease - Heart Rhythm
    This review discusses ion channels that contribute to action potential formation in healthy hearts and their role in inherited and acquired diseases.
  9. [9]
    Chapter 2. Ionic Mechanisms of Action Potentials
    In the presence of TEA the initial phase of the action potential is identical, but note that it is much longer and does not have an after-hyperpolarization.
  10. [10]
    Physiology, Cardiac Repolarization Dispersion and Reserve - NCBI
    Apr 17, 2023 · Characteristically, a pacemaker action potential has only three phases, designated phases zero, three, and four. Phase zero is the phase of ...
  11. [11]
    Ionic basis of spontaneous electrical activity of cardiac muscle
    Sep 11, 2024 · A comparison of the ionic events during the cardiac action potentials in the myocyte and the pacemaker cell.
  12. [12]
    Ionic events responsible for the cardiac resting and action potential
    The rapid depolarization phase of the action potential is mediated in part by an ionic channel that resembles the sodium ion (Na+) channel of nerve.
  13. [13]
    Cardiac Action Potentials - The Student Physiologist
    Typical neural AP duration is around 1ms and those of skeletal muscle are roughly 2-5ms, whereas cardiac action potentials range from 200-400ms. Nervous and ...
  14. [14]
    Cardiac Excitation-Contraction Coupling - CV Physiology
    Excitation-contraction coupling (ECC) is the process whereby an action potential triggers a myocyte to contract, followed by subsequent relaxation.
  15. [15]
    Calcium and Excitation-Contraction Coupling in the Heart
    Jul 7, 2017 · The process of excitation–contraction (E–C) coupling links the electric excitation of the surface membrane (action potential) to contraction.
  16. [16]
    Cardiac excitation–contraction coupling | Nature
    Jan 10, 2002 · Cardiac excitation–contraction coupling is the process from electrical excitation of the myocyte to contraction of the heart (which propels ...
  17. [17]
    Action Potentials - CV Physiology
    There are three general types of cardiac action potentials that are distinguished, in part, by the presence or absence of spontaneous pacemaker activity.<|control11|><|separator|>
  18. [18]
    Sunao Tawara: a father of modern cardiology - PubMed
    Tawara advanced heart conduction knowledge, identified the pathway for atrioventricular conduction, and his work provided the basis for electrocardiography.
  19. [19]
    12.4 The Action Potential - Anatomy and Physiology 2e | OpenStax
    Apr 20, 2022 · All of this takes place within approximately 2 milliseconds (Figure 12.24). While an action potential is in progress, another one cannot be ...
  20. [20]
    Cardiac Action Potential - an overview | ScienceDirect Topics
    The entire action potential in a skeletal muscle lasts only 1 to 2 ms. A cardiac action potential lasts about 100 times longer (100–250 ms). Prolongation of the ...
  21. [21]
    The inward rectifier current (IK1) controls cardiac excitability and is ...
    The cardiac inwardly rectifying potassium current (I(K1)) stabilizes the resting membrane potential and is responsible for shaping the initial depolarization ...
  22. [22]
    Non-Pacemaker Action Potentials - CV Physiology
    The resting membrane potential is very negative during phase 4 (about -90 mV) because potassium channels are open (K+ conductance [gK] and K+ currents are high) ...Missing: IK1 | Show results with:IK1
  23. [23]
    Electrophysiology of Sinoatrial Node: Basic Concepts
    Diastolic depolarization during phase 4 of the SAN AP is the fundamental pacemaker potential and underlies SAN automaticity [17]. It brings the membrane ...Missing: paper | Show results with:paper
  24. [24]
    Cardiac Muscle and Electrical Activity | Anatomy and Physiology II
    Action potentials are considerably different between cardiac conductive cells and cardiac contractive cells. While Na+ and K+ play essential roles, Ca2+ is ...Conduction System Of The... · Sinoatrial (sa) Node · Electrocardiogram
  25. [25]
    The Role of the Funny Current in Pacemaker Activity
    Feb 19, 2010 · This review address the main properties of funny channels, their contribution to cardiac pacemaking and how the concept of funny channel ...
  26. [26]
    The Calcium and Voltage Clocks in Sinoatrial Node Automaticity - NIH
    The idea of a Ca2+ clock suggests that the mechanism of automaticity is the same as that of delayed afterdepolarization (DAD), which occurs when there is a SR ...
  27. [27]
    Normal processes of cardiac excitation and electrical activity
    Jan 9, 2025 · The normal cardiac action potential has five phases: rapid depolarization, early repolarization, plateau, repolarization, and resting potential.
  28. [28]
    Alterations of Na+ Currents in Myocytes From Epicardial Border ...
    The peak INa density was 12.8±0.6 pA/pF in NZs ... Effects of intracellular calcium on sodium current density in cultured neonatal rat cardiac myocytes.
  29. [29]
    Normal and Abnormal Electrical Conduction - CV Physiology
    These specialized fibers conduct the impulses at a very rapid velocity (about 2 m/sec). The bundle branches then divide into an extensive system of Purkinje ...
  30. [30]
    A model of the ventricular cardiac action potential. Depolarization ...
    The fast sodium current, INa, is characterized by fast upstroke velocity (Vmax = 400 V/sec) and slow recovery from inactivation.Missing: equation | Show results with:equation
  31. [31]
    Phase 1 repolarization rate defines Ca2+ dynamics and contractility ...
    Apr 18, 2019 · 4 A. Second, the early repolarization during phase 1 is slower in endocardium than in epicardium (4.66 ± 0.76 ms vs. 2.35 ± 0.37 ms, n = 10 ...
  32. [32]
    Action Potential Characteristics and Arrhythmogenic Properties of ...
    The action potentials were characterized by a prominent phase 1 repolarization and a very distinct phase 2, which occurred usually between −15 and −50 mV.
  33. [33]
    How does the shape of the cardiac action potential control calcium ...
    These changes include reductions in the rate of depolarization and peak depolarization during phase 0, a decrease in the repolarization during phase 1 (or even ...
  34. [34]
    A dynamic model of the cardiac ventricular action potential. I ...
    A mathematical model of the cardiac ventricular action potential is presented. In our previous work, the membrane Na+ current and K+ currents were ...Missing: equation | Show results with:equation<|control11|><|separator|>
  35. [35]
    Inducing Ito,f and phase 1 repolarization of the cardiac action ... - NIH
    The fast transient outward potassium current (Ito,f) plays a key role in phase 1 repolarization of the human cardiac action potential (AP) and its reduction ...
  36. [36]
    Transient Outward K+ Current (Ito) Underlies the Right Ventricular ...
    Jul 11, 2018 · The results showed that shorter action potential duration in the right ventricle (RV) was associated with focal activity during pVT initiation.
  37. [37]
    Two Components of the Delayed Rectifier K + Current in Ventricular ...
    The important outward currents responsible for repolarization of the cardiac action potential are carried by K+ ions. Unlike the other ionic currents, K+ ...Missing: seminal papers<|control11|><|separator|>
  38. [38]
    Calcium and Excitation-Contraction Coupling in the Heart - PMC - NIH
    Jul 7, 2017 · Much of the Ca needed for contraction comes from the sarcoplasmic reticulum and is released by the process of calcium-induced calcium release.Missing: seminal paper
  39. [39]
    Insights into Cardiac IKs (KCNQ1/KCNE1) Channels Regulation
    Dec 11, 2020 · Phase 3 begins when enough of the delayed rectifier Kv channels (IKs and IKr) are activated, causing a more outward K+ current than inward Ca2+ ...
  40. [40]
    Cardiac Delayed Rectifier Potassium Channels in Health and Disease
    During the plateau phase (phase 2), calcium entry via L-type calcium channels triggers contraction. Counter-balancing the calcium influx, potassium ions pass ...Missing: papers | Show results with:papers
  41. [41]
    Cardiac Action Potential - an overview | ScienceDirect Topics
    Final repolarization during phase 3 results from K+ efflux through the IK1 channels, which open at potentials negative to −20 mV.4. Phase 4: Restoration of ...
  42. [42]
    Characterization and functional consequences of delayed rectifier ...
    In summary, rapidly activating I Kr provides a delayed voltage-dependent (and functionally time-independent) outward transient during ventricular repolarization ...
  43. [43]
    Torsade de Pointes - StatPearls - NCBI Bookshelf - NIH
    Torsades de Pointes is associated with QTc prolongation, which is the heart rate adjusted lengthening of the QT interval. The rhythm may terminate spontaneously ...
  44. [44]
    Rate-dependent shortening of action potential duration increases ...
    Cardiac Excitation and Contraction. Share on. Rate-dependent shortening of action potential duration increases ventricular vulnerability in failing rabbit heart.
  45. [45]
    Positive rate‐dependent action potential prolongation by modulating ...
    Jun 24, 2022 · The use of a combination of IKs activators and IKr and IK1 blockers results in positive rate dependence and leads to APD prolongation that potentially ...
  46. [46]
    Voltage-gated sodium channels (Na V ): Introduction
    Voltage-gated sodium channels are responsible for action potential initiation and propagation in excitable cells, including nerve, muscle, and neuroendocrine ...
  47. [47]
    Structure of the Cardiac Sodium Channel - PMC - PubMed Central
    Voltage-gated sodium channel Nav1.5 generates cardiac action potentials and initiates the heartbeat. Here we report structures of NaV1.5 at 3.2–3.5 Å resolution ...
  48. [48]
    Biology of cardiac sodium channel Na v 1.5 expression
    Although Nav1.5 α-subunits can act as voltage-gated sodium channels in their own right, in vivo the Na+ channel is part of a large multiprotein complex.<|control11|><|separator|>
  49. [49]
  50. [50]
    Pharmacological Profile of the Sodium Current in Human Stem Cell ...
    Dec 10, 2019 · The current density of Nav1.5 and Nav1.5+β1 at –20 mV amounted to −119 ± 21 pA/pF (n = 19) and −198 ± 41 ...
  51. [51]
    Higher Sodium Channel Excitability in Cardiac Purkinje Fibers - JACC
    A higher expression of β1 and β3 subunits contributes to higher sodium channel excitability in cardiac Purkinje fibers, making them more susceptible to MEPPC.
  52. [52]
    Life Cycle of the Cardiac Voltage-Gated Sodium Channel NaV1.5
    Dec 16, 2020 · The NaV1.5 channel mediates the rapid influx of sodium ions (Na+), which triggers cardiac action potential (AP), induces rapid depolarization, ...
  53. [53]
    Cardiac Sodium Channel Nav1.5 Mutations and Cardiac Arrhythmia
    Mutations of Nav1.5 have been linked to a variety of cardiac disease such as long QT syndrome (LQTs), Brugada syndrome, cardiac conduction defect, atrial ...
  54. [54]
    Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs
    Although cardiac sodium channel blocking drugs can exert antiarrhythmic actions, they can also provoke life-threatening arrhythmias through a variety of ...
  55. [55]
    L-type Ca2+ channels in heart and brain - PMC - PubMed Central
    L-type calcium channels (Cav1) represent one of the three major classes (Cav1–3) of voltage-gated calcium channels. They were identified as the target of ...
  56. [56]
    Functional Roles of Ca v 1.3 (α 1D ) Calcium Channel in Sinoatrial ...
    We directly examined the role of the Ca v 1.3 (α 1D ) Ca 2+ channel in the sinoatrial (SA) node by using Ca v 1.3 Ca 2+ channel-deficient mice.
  57. [57]
    Pathophysiology of Ca v 1.3 L-type calcium channels in the heart
    Here, we review the functional role, expression levels, and regulation of Ca v 1.3 in the heart, including in the context of cardiac diseases.
  58. [58]
    T-Type Voltage-Gated Calcium Channels: Potential Regulators of ...
    Nov 19, 2024 · This review provides a detailed examination of T-type voltage-gated calcium channels, highlighting their structure, electrophysiology, biophysics, expression ...
  59. [59]
    Cardiac T-type Ca2+ channels in the heart - ScienceDirect.com
    In the heart, voltage-dependent Ca2+ channels are thought to mediate Ca2+ influx in response to membrane depolarization and regulate excitability, contraction, ...Missing: CICR | Show results with:CICR
  60. [60]
    Kinetic Properties of the Cardiac L-Type Ca2+ Channel and Its Role ...
    L-type Ca2+ channels typically begin to activate between −40 and −30 mV and peak current is reached between 0 and +10 mV. Fig. 3 C shows simulated voltage- ...
  61. [61]
    Calcium-dependent inactivation controls cardiac L-type Ca 2+ ...
    Feb 27, 2019 · During a cardiac action potential, the activity of L-type Ca2+ channels (LTCCs) is modulated by voltage- and calcium-dependent inactivation ...Missing: ICa, | Show results with:ICa,
  62. [62]
    T-type channels in the sino-atrial and atrioventricular pacemaker ...
    Feb 27, 2014 · Voltage-dependent T-type Ca(2+) channels are an integral part of the complex mechanism underlying pacemaking. T-type channels also contribute ...
  63. [63]
    Functional role of voltage gated Ca2+ channels in heart automaticity
    Feb 2, 2015 · However, growing evidence shows that VGCCs are important regulators of the pacemaker mechanisms and play also a major role in atrio-ventricular ...
  64. [64]
    Verapamil - StatPearls - NCBI Bookshelf
    Verapamil is a non-dihydropyridine calcium channel blocker. Calcium channel blockers inhibit the entry of calcium ions into the slow L-type calcium channels.
  65. [65]
    Calcium Channel Blockers - StatPearls - NCBI Bookshelf
    Feb 22, 2024 · Dihydropyridine drugs are used to treat hypertension, coronary artery disease, and chronic stable angina. Non-dihydropyridine drugs are used to ...
  66. [66]
    The modulation of calcium and chloride channels induces ... - NIH
    Jan 1, 2025 · This study demonstrates that regulation of ion channels plays a crucial role in determining the fate of cardiac cells.
  67. [67]
    Regulation of Cardiac Cav1.2 Channels by Calmodulin - MDPI
    2 Ca2+ channels, a type of voltage-gated L-type Ca2+ channel, are ubiquitously expressed, and the predominant Ca2+ channel type, in working cardiac myocytes.
  68. [68]
    Molecular physiology of cardiac potassium channels
    Potassium currents in the myocardium can be classified into one of two general categories: 1) inward rectifying currents such as IK1, IKACh, and IKATP; and 2) ...
  69. [69]
    Dynamical Mechanisms of Pacemaker Generation in IK1 ...
    This discrepancy is at least in part due to the difference in IK1 density, which is much higher in ventricular cells than in atrial or Purkinje cells (56,57).
  70. [70]
    Pharmacology of cardiac potassium channels - Oxford Academic
    Cardiac K+ channels determine the resting membrane potential, the heart rate, the shape and duration of the action potential and are important targets for the ...Introduction · Cardiac voltage-gated channels · Inward rectifying K channels
  71. [71]
    Molecular Basis of the Long-QT Syndrome Associated with Deafness
    May 29, 1997 · We discovered that a patient with the Jervell and Lange-Nielsen syndrome had a homozygous mutation of KVLQT1. ... HERG mutations cause long QT ...
  72. [72]
    KCNQ1 mutations associated with Jervell and Lange-Nielsen ...
    This study presents biallelic gene mutations in KCNQ1 in Asian Indian patients with AR JLNS and RWS. It adds to the scant worldwide literature of mutation ...Missing: hERG LQT2
  73. [73]
    Influence of baseline QTc on sotalol‐induced prolongation of ...
    Dec 17, 2021 · The most important finding of the study is that baseline QTc does not significantly influence the amplitude of QTc prolongation with sotalol, an ...
  74. [74]
    The HCN domain couples voltage gating and cAMP response ... - eLife
    Nov 26, 2019 · Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels control spontaneous electrical activity in heart and brain.
  75. [75]
    New Therapeutic Targets in Cardiology | Circulation
    May 14, 2013 · HCN channels belong to the superfamily of voltage-gated pore-loop cation channels. Four isoforms (HCN1–HCN4) with a high homology have been ...
  76. [76]
    Molecular Mapping of Sinoatrial Node HCN Channel Expression in ...
    The hyperpolarization-activated current, If, plays an important role in sinoatrial node (SAN) pacemaking. Surprisingly, the distribution of ...
  77. [77]
    HCN4 channels sense temperature and determine heart rate ...
    Mar 1, 2025 · Based on various knockout models, HCN4 is responsible for about 75 % of the current in SAN cells35,36,37.Missing: percentage | Show results with:percentage
  78. [78]
    Biological Pacemakers: Present and Future | Circulation Research
    Mar 28, 2024 · Here, we will review current approaches to generate biological pacemakers and discuss recent advances in refining engineered biological pacemakers.
  79. [79]
    Properties of ivabradine-induced block of HCN1 and HCN4 ... - NIH
    Ivabradine is a 'heart rate-reducing' agent able to slow heart rate, without complicating side-effects. Its action results from a selective and specific block ...
  80. [80]
    Hyperpolarization‐Activated Cyclic Nucleotide‐Gated Channels and ...
    Jun 7, 2013 · The majority of studies have focused on the modifications in functional and molecular properties of If and HCN channel expression during cardiac ...
  81. [81]
    Connexins in the Heart: Regulation, Function and Involvement in ...
    Interestingly, the distribution patterns of Cx40 and Cx43 are, to a large extent, comparable in rat, guinea pig, porcine, bovine and human hearts, both in ...
  82. [82]
    Remodelling of gap junctions and connexin expression in diseased ...
    Three principal connexins are expressed in cardiac myocytes, connexin43 (Cx43), Cx40, and Cx45. Although Cx43 predominates in the heart as a whole, it is ...2. Gap Junction Organization... · 4.1 Acute Cardiac Ischaemia · 4.5 Atrial Arrhythmia
  83. [83]
    Cardiac gap junctions: three distinct single channel conductances ...
    Our results indicate that Cx43-gap junction channels may exhibit three conductance levels (21 pS, 40-45 pS and 70 pS), depending on the phosphorylation state of ...
  84. [84]
    Cardiac gap junction channels: modulation of expression and ...
    In the heart, intercellular gap junction channels constructed from connexin molecules are crucial for conduction of the electric impulse. Cardiomyocytes can be ...
  85. [85]
    Spatial Distribution of Connexin43, the Major Cardiac Gap Junction ...
    The major cardiac gap junction protein is connexin43 (Cx43). The distribution of Cx43 has been studied by immunofluorescence to visualize the electrical ...
  86. [86]
    Role of gap junctions in the propagation of the cardiac action potential
    Gap junctions play a pivotal role for the velocity and the safety of impulse propagation in cardiac tissue.Abstract · General aspects of the role of... · Gap junctions, the “truth and...
  87. [87]
    Altered connexin43 expression produces arrhythmia substrate in ...
    These data demonstrate that reduced Cx43 expression produces uncoupling between transmural muscle layers leading to slowed conduction and marked dispersion of ...
  88. [88]
    role of altered intercellular coupling in arrhythmias induced by acute ...
    These observations suggest that uncoupling induced by ischemia is associated with dephosphorylation of Cx43, accumulation of nonphosphorylated Cx43 within ...
  89. [89]
    Regulation of cardiac gap junctions by protein phosphatases - PMC
    Sufficient connexin-mediated intercellular coupling is critical to maintain gap junctional communication for proper cardiac function.
  90. [90]
    Selectivity of Connexin 43 Channels Is Regulated Through Protein ...
    May 18, 2006 · We show here that the selective permeability of Cx43 junctions is regulated through protein kinase C (PKC)-dependent phosphorylation at serine ...
  91. [91]
    Cardiac action potential repolarization revisited - PubMed Central
    In healthy mammalian hearts the action potential (AP) waveform initiates and modulates each contraction, or heartbeat. As a result, AP height and duration ...
  92. [92]
    Strength-interval relation for ventricular functional refractoriness
    Procainamide shifted the effective RP and local and remote functional RP strength-interval curves uniformly to the right without altering their relation.
  93. [93]
    Electrophysiological characteristics of pressure overload-induced ...
    Thus, the relative refractory period and supranormal period after ERP were prolonged. This change increased the window of vulnerability and facilitated the ...
  94. [94]
    Intracoronary Infusion of Catecholamines Causes Focal Arrhythmias ...
    May 9, 2008 · These arrhythmias are closely associated with a shortened refractory period and a large gradient of the spatial distribution of refractoriness ...
  95. [95]
    Class III Antiarrhythmics (Potassium Channel Blockers)
    Potassium channels are also responsible for repolarizing slow-response action potentials in the sinoatrial and atrioventricular nodes. Delayed repolarization ...
  96. [96]
  97. [97]
    A Computer Model of Normal Conduction in the Human Atria
    Reported times for total activation of the right atrial free wall vary. Canavan et al indicate a duration of just >80 ms. Other studies, however, assert a time ...<|separator|>
  98. [98]
    Atrioventricular Node - an overview | ScienceDirect Topics
    (3) After reaching the atrioventricular node (AV), there is a delay of approximately 100 ms that allows the atria to complete pumping blood before the impulse ...
  99. [99]
    Cardiac Action Potential - an overview | ScienceDirect Topics
    Under normal conditions, ventricular cells do not undergo pacemaker depolarization but have resting membrane potentials (–85 mV) close to EK. The impulse ...
  100. [100]
    Cardiovascular Physiology - Veterian Key
    May 1, 2025 · Table 33.4 Intrinsic rate, action potential duration, and conduction velocity in cardiac tissues of larger mammals. ... 2–4 m/s for all animals.<|separator|>
  101. [101]
    Electrocardiogram (EKG, ECG) - CV Physiology
    The different waves that comprise the ECG represent the sequence of depolarization and repolarization of the atria and ventricles. ... (80-100 ms) in duration.Missing: activation 40-60
  102. [102]
    Embryology, Heart - StatPearls - NCBI Bookshelf - NIH
    The cardiovascular system's embryological development begins with cardiac progenitor cells' migration in the epiblast, just lateral to the primitive streak.
  103. [103]
    Normal and abnormal development of the cardiac conduction system
    In this review we will focus on embryonic development of the CCS in relation to clinical arrhythmias, as well as on specific cardiac conduction abnormalities.
  104. [104]
    Ectopic Foci - CV Physiology
    Ectopic foci are abnormal pacemaker sites within the heart (outside the SA node) that display automaticity. Their pacemaker activity, however, is normally ...
  105. [105]
    Effects of thyroid hormone on action potential and ... - PubMed - NIH
    Treatment of hypothyroid ventricular myocytes with T(3) (0.1 microM) for 5 min significantly shortened APD by 24% to 115 +/- 10 ms. T(3) similarly shortened APD ...
  106. [106]
    Effects of thyroid hormone on action potential and repolarizing ...
    Treatment of hypothyroid ventricular myocytes with T3 (0.1 μM) for 5 min significantly shortened APD by 24% to 115 ± 10 ms. T3 similarly shortened APD in ...Missing: ICa, | Show results with:ICa,
  107. [107]
    Rapid and MR-Independent I K1 Activation by Aldosterone during ...
    In microelectrode experiments, aldosterone (10 and 100 nmol/L, n=7 respectively) increased the action potential duration (APD) dispersion at 90% between ...Missing: enhances | Show results with:enhances
  108. [108]
    IK1 Channel Agonist Zacopride Alleviates Cardiac Hypertrophy and ...
    Aug 26, 2019 · We hypothesized that enhancement of IK1 currents is a compensation for IK1 deficit and a novel modulation for cardiac Ca2+ homeostasis and ...
  109. [109]
    Amiodarone - StatPearls - NCBI Bookshelf - NIH
    Nov 12, 2023 · ... heart during phase 3 of the cardiac action potential. This potassium channel-blocking effect results in increased action potential duration ...
  110. [110]
    β-blockers augment L-type Ca2+ channel activity by targeting ...
    β-blockers are thought to reduce cAMP signaling because they either reduce basal activity of βARs or block agonist-induced receptor activation.
  111. [111]
    Beta-blockers | Deranged Physiology
    Jul 19, 2025 · So: decrease the concentration of cAMP by blocking the β1 receptor, and the If current slows down, making the pacemaker cells depolarise less ...
  112. [112]
    HCN Channels and Heart Rate - PMC - PubMed Central - NIH
    ... 20–30% heart rate reduction with If-current blockers). ... if current inhibition with ivabradine: A new therapeutic perspective in cardiovascular disease.
  113. [113]
    Sex Difference in Risk of Torsade de Pointes With d,l-Sotalol
    TdP was also more likely to develop at higher d,l-sotalol doses, which is expected because QT interval progressively prolongs as drug dose increases. Patients ...
  114. [114]
    Maturation of human cardiac organoids enables complex disease ...
    Jun 25, 2025 · Using extensive characterization, drug testing and disease modeling experiments, we demonstrate that these DM-hCOs are a faithful model system ...
  115. [115]
    Electrophysiological mechanisms of long and short QT syndromes
    Nov 26, 2016 · In this article, the molecular determinants of the AP duration and the causes of long and short QT syndromes (LQTS and SQTS) are explored.
  116. [116]
    Long QT syndrome: from channels to cardiac arrhythmias - PubMed
    Long QT syndrome, a rare genetic disorder associated with life-threatening arrhythmias, has provided a wealth of information about fundamental mechanisms ...
  117. [117]
    Cellular and ionic mechanisms responsible for the Brugada syndrome
    Strong sodium channel block, among other modalities, can accentuate the action potential notch in right ventricular epicardial cells, eventually leading to loss ...
  118. [118]
    Cardiac Alternans: From Bedside to Bench and Back
    Jan 5, 2023 · Cardiac alternans arises from dynamical instabilities in the electrical and calcium cycling systems of the heart, and often precedes ventricular arrhythmias ...Ca-Driven Alternans · Spatially Discordant... · Alternans And...<|separator|>
  119. [119]
    The Mechanisms of Calcium Cycling and Action Potential Dynamics ...
    The mechanisms of alternans are complex and the bi-directional coupling between beat-to-beat cytosolic Ca2+ handling and membrane potential regulation is a key ...
  120. [120]
    Mechanistic insights into spontaneous transition from cellular ...
    We believe this study provides new insights into underlying the mechanism, by which cellular cardiac alternans spontaneously evolves into cardiac arrhythmias.
  121. [121]
    Overview of Basic Mechanisms of Cardiac Arrhythmia - PMC
    Spontaneous activity is the result of diastolic depolarization caused by a net inward current during phase 4 of the action potential, which progressively brings ...
  122. [122]
    Mechanisms of Cardiac Arrhythmias
    The 3 main mechanisms responsible for cardiac arrhythmias are automaticity, triggered activity, and reentry.Missing: review | Show results with:review
  123. [123]
    Antiarrhythmic Medications - StatPearls - NCBI Bookshelf - NIH
    Antiarrhythmic medications play a pivotal role in managing various cardiac rhythm disorders, and their classification under the Vaughan-Williams system ...Antiarrhythmic Medications · Indications · Mechanism Of Action
  124. [124]
    Modernized Classification of Cardiac Antiarrhythmic Drugs
    Oct 22, 2018 · Quinidine is additionally proarrhythmic under conditions of prolonged AP recovery, at least partially reflecting its additional IK-blocking ...Abstract · Modernized Scheme Based On... · Recapitulation
  125. [125]
    Class I Antiarrhythmics (Sodium-Channel Blockers)
    These drugs bind to and block fast sodium channels that are responsible for rapid depolarization (phase 0) of fast-response cardiac action potentials.General Pharmacology · Effects On Depolarization · Effects On Repolarization
  126. [126]
    Cardiac Pacemakers: Function, Troubleshooting, and Management
    In this first part of a 2-part review, we describe indications, implant-related complications, basic function/programming, common pacemaker-related issues, and ...
  127. [127]
    Implantable Cardioverter Defibrillator (ICD)
    Oct 29, 2024 · Implantable cardioverter defibrillators or ICDs are useful in preventing sudden death for those with a life-threatening arrhythmia.
  128. [128]
    2017 AHA/ACC/HRS Guideline for Management of Patients With ...
    Aug 1, 2018 · 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
  129. [129]
    Evolution of Pacemakers and Implantable Cardioverter Defibrillators ...
    Oct 2, 2023 · An ICD is a medical gadget that monitors and treats irregular cardiac rhythms, including severe arrhythmias, such as VT and ventricular ...
  130. [130]
    Gene Therapy for Cardiac Arrhythmias: Mechanisms, Modalities and ...
    Jul 30, 2025 · Gene Therapy Approaches for Biological Pacemaker Development ... Moreover, dual gene delivery strategies—combining HCN channel overexpression ...
  131. [131]
    A Better Understanding of Atrial-like and Ventricular-like Action ... - NIH
    Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) tend to show a mixed population of action potential (AP) types, including atrial-like (A-like) ...
  132. [132]
    Specific induction of right ventricular-like cardiomyocytes from ...
    Sep 26, 2025 · Applications employing human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) require well-characterized, chamber-specific hPSC-CMs.
  133. [133]
    Atrial-specific hiPSC-derived cardiomyocytes in drug discovery and ...
    This highlights the importance of hiPSC-CMs as a powerful tool in cardiotoxicity and drug screening platforms [25]. Advances in stem cell research and specific ...<|separator|>
  134. [134]
    Optogenetic modulation of cardiac action potential properties may ...
    Jun 8, 2021 · Optogenetic modulation of cardiac action potential properties may prevent arrhythmogenesis in short and long QT syndromes.
  135. [135]
    Efficient and sustained optogenetic control of sensory and cardiac ...
    Jul 28, 2025 · Optogenetic control is used to manipulate the activity of specific cell types in vivo for a variety of biological and clinical applications.
  136. [136]
    Cardiac ventricular repolarization reserve: a principle for ... - NIH
    It is concluded that repolarization reserve should be considered by safety pharmacologists to better understand, predict and prevent previously unexplained ...
  137. [137]
    Repolarization Reserve and Action Potential Dynamics in Failing ...
    Feb 8, 2018 · APD alternans is a beat-to-beat oscillation that is associated with increased arrhythmia vulnerability and HF. Importantly, abnormal Ca2+ ...